Steroids for Swelling After Plastic Surgery: What a Single Dose of Dexamethasone Does and Does Not Do

Somewhere in the first ten minutes of most rhinoplasties, facelifts, and eyelid operations in this country, an anesthesiologist pushes 8 to 10 milligrams of dexamethasone into the intravenous line. It is not on the consent form as a line item. It rarely comes up in the consultation. It is simply part of the furniture of modern cosmetic anesthesia, and for the most part it deserves to be. Steroids for swelling after plastic surgery are one of the few perioperative habits that have been tested repeatedly in randomized trials and survived.

What has not survived, or at least has never been properly tested, is the expansion of that single dose into something larger: a six-day oral taper handed over at discharge, a second and third injection at the follow-up visits, a steroid prescribed to every patient regardless of the operation because the last patient asked for one. Dexamethasone is a cheap, potent, and generally well-tolerated drug, which is exactly the profile that lets a good idea drift into an unexamined one. The question a patient should be asking is not whether the steroid works. It is which steroid plan the evidence supports, and whether the one in their chart is that one.

What a single intravenous dose actually does

The short answer: one dose of 8 to 10 milligrams of intravenous dexamethasone given at the start of surgery reduces measurable facial edema and ecchymosis in the first two to three days after rhinoplasty and facial surgery, and cuts the incidence of postoperative nausea and vomiting by roughly a quarter relative to placebo.

The rhinoplasty literature is where the swelling data is strongest, because rhinoplasty produces predictable periorbital bruising that can be photographed and graded. A 2011 meta-analysis in Plastic and Reconstructive Surgery pooled the randomized trials and found that a single preoperative dose reduced periorbital edema and ecchymosis at 24 and 48 hours, with the effect fading by the end of the first week. Later systematic reviews, including work published in JAMA Facial Plastic Surgery, reached the same conclusion: the benefit is real, it is front-loaded, and it does not change what the nose looks like at six months. Steroids buy a more comfortable first week. They do not buy a better result.

The nausea effect is arguably the more valuable of the two. Dexamethasone is one of the three drugs, alongside ondansetron and droperidol, that the Society for Ambulatory Anesthesia's consensus guidelines list as first-line prophylaxis against postoperative nausea and vomiting, and the landmark IMPACT trial in the New England Journal of Medicine found that each of those agents independently reduced the risk by about 26 percent relative to placebo. That matters in cosmetic surgery specifically, because vomiting after a facelift or rhinoplasty raises venous pressure in the face and is a recognized contributor to hematoma. A drug that reduces both swelling and the retching that causes bleeding is doing two jobs at once, and doing them from a single vial that costs less than a cup of coffee. We have written about nausea after cosmetic surgery at length; dexamethasone is a large part of why it is less common than it used to be.

Where the evidence stops

The short answer: there is no good trial evidence that extending dexamethasone beyond the first 24 hours, whether as repeated injections or as an oral taper, produces any further reduction in swelling, and the studies that have looked found the benefit of the extra doses was small or absent.

This is the part that patients are rarely told, and it is worth being precise about. Several rhinoplasty trials have compared a single preoperative dose against multiple-dose regimens continued for 24 to 72 hours. The consistent finding is that the extended regimens produce, at best, a marginal further reduction in edema on day two or three and no difference by day seven. The 2011 meta-analysis noted the trend toward benefit from extended dosing but described the evidence as insufficient, and nothing published since has changed that reading. For facelift, blepharoplasty, and body procedures, the data on extended steroids is thinner still. Much of what circulates as standard practice is the extrapolation of a rhinoplasty finding to operations that were never studied.

The oral taper is the most common form of this drift. A methylprednisolone dose pack, the six-day blister card that starts at 24 milligrams and steps down to 4, is prescribed after cosmetic surgery by a substantial number of practices, and there is no randomized trial in the aesthetic literature showing that it reduces swelling beyond what the intraoperative dose already achieved. The swelling timeline after any operation is governed mostly by tissue trauma, dissection plane, and lymphatic drainage, none of which a week of oral steroid changes. What the taper reliably does is suppress the inflammatory phase of healing during precisely the days when that phase is supposed to be doing its work.

"

One dose of dexamethasone at the start of surgery is among the best-supported habits in cosmetic anesthesia. The taper pack handed over at discharge is a tradition wearing the first dose's evidence as a costume.

"

The wound-healing and blood-sugar tradeoff

The short answer: a single dose has not been shown to impair wound healing or raise infection rates in healthy patients, but multi-day courses measurably delay collagen deposition and epithelialization, raise blood glucose for 12 to 24 hours after each dose, and in diabetic or prediabetic patients can push sugars into a range that itself impairs healing.

Corticosteroids blunt the inflammatory phase of wound healing, and inflammation is not a side effect of healing but its first step. Fibroblasts are recruited by inflammatory signaling, collagen is laid down in the days that follow, and epithelial cells migrate across the wound under the same cues. The classic surgical teaching, drawn from patients on chronic steroids, is that wounds heal slowly and dehisce more often, and that teaching is correct for chronic exposure. The perioperative question is whether one or two doses matter, and the answer from large surgical series is reassuring: a 2013 systematic review in the Annals of Surgery covering more than 4,000 patients across general surgical trials found no increase in wound infection or dehiscence with single-dose dexamethasone. The line the evidence draws is between a dose and a course.

Blood sugar is the underappreciated cost. Dexamethasone reliably raises glucose, and in patients who are not known to be diabetic the rise is transient and unremarkable. In the roughly one in three American adults with prediabetes, many of whom do not know it, the rise can be substantial, and the American Diabetes Association's guidance on perioperative glucose control notes that even short steroid exposure can produce hyperglycemia that requires monitoring. Elevated glucose in the first 48 hours after surgery is independently associated with higher surgical site infection rates. A practice that gives dexamethasone to a patient with an unmeasured hemoglobin A1c, then sends them home with a taper pack, is stacking two glucose insults on a wound it has not checked the soil conditions for. The same logic applies to patients who arrive with other healing risks, the ones we covered in the piece on skin necrosis: the steroid margin that a healthy 30-year-old rhinoplasty patient can spend freely is not the same margin in a 62-year-old facelift patient with a thin flap and a fasting glucose nobody drew.

Local steroid injections: a different drug, a different question

The short answer: triamcinolone injected directly into the nasal tip or into a scar after surgery is a separate intervention from systemic dexamethasone, with its own evidence for reducing supratip swelling and hypertrophic scarring, and its own well-documented risks of fat atrophy, skin thinning, and depigmentation when it is overused.

Patients sometimes conflate the two, and some practices let them. A small dose of triamcinolone acetonide injected into a persistently swollen supratip weeks after rhinoplasty has reasonable support in the facial plastic surgery literature for reducing that specific swelling and preventing the fibrous "pollybeak" deformity. It works because the drug is placed where the problem is and acts locally on fibroblasts. The same drug injected into a developing hypertrophic scar after a breast or body procedure is a mainstay of scar management endorsed in the international scar guidelines. Neither of these is the same decision as a systemic steroid given for generalized swelling, and neither should be routine. The complications of local steroid are dose-dependent and cumulative: subcutaneous fat atrophy that leaves a visible dent, thinning of the overlying skin, telangiectasia, and lightening of the skin that is more visible and more persistent in darker skin types. The American Academy of Dermatology's guidance on intralesional corticosteroids treats these as expected consequences of excess, not rare surprises. A tip injection is a targeted tool used once or twice for a specific problem. Monthly injections into a nose that "still looks a little swollen" are a way to manufacture a new problem while chasing the old one.

The honest summary

A single intravenous dose of dexamethasone at the start of cosmetic surgery is supported by randomized trials and meta-analyses: it reduces swelling and bruising for the first two to three days, cuts postoperative nausea and vomiting by about a quarter, and in healthy patients has not been shown to impair wound healing or raise infection risk. That is the steroid plan the evidence endorses, and a patient should expect to receive it. Everything beyond it stands on weaker ground. Repeated doses in the first three days add little, oral taper packs after discharge have no trial support in aesthetic surgery, and both extend steroid exposure into the days when the inflammatory phase of healing is supposed to be running. The costs of that extension are real and quiet: delayed collagen deposition, transient hyperglycemia that becomes consequential in undiagnosed prediabetes, and, with local triamcinolone, fat atrophy and skin changes that are harder to fix than the swelling they were treating. The swelling from a well-executed operation resolves on its own timeline, and no steroid regimen moves the six-month result. Ask what steroid you are getting, ask why, and ask whether anyone has drawn your blood sugar. The answers tell you as much about the practice as they do about the drug.